Vasoactive-inotropic Support and Levosimendan Use After Lung Transplantation (VASO_LUTX)

Policlinico Hospital

Status: Completed

Conditions: Lung Transplant; Complications

Treatments: Drug: Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan

Study type: Observational

Funder types: Other

Identifiers

NCT05702333

VASO_LUTX

Details and patient eligibility

About

Bilateral Lung transplantation (LUTX) is performed in selected patients with end-stage respiratory failure. During surgery, pulmonary arteries are sequentially cross-clamped. This can cause acute heart failure and hemodynamic instability that eventually persist into the postoperative period, leading to the need for prolonged vasoactive support in the postoperative Intensive Care Unit. Levosimendan is a relatively new vasoactive-inotropic drug, with different pharmacodynamic properties.

This observational retrospective cohort study primarily aims 1) to describe the need for prolonged vasoactive support; 2) to evaluate the risk factors for prolonged vasoactive support; 3) to assess the impact of prolonged vasoactive support on outcomes. The secondary aim is to describe the use of Levosimendan in this cohort of patients.

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Intensive Care Unit admission after Double Lung Transplant surgery.

Exclusion criteria

1. single Lung Transplantation;
2. re-transplantation.

Trial design

150 participants in 2 patient groups

Vasoactive-inotropic drug use (VASO+)

Description:

All patients treated with vasoactive-inotropic drugs (epinephrine, norepinephrine, dobutamine, dopamine, and levosimendan) after 12 hours after Intensive Care Unit Admission were retrospectively classified in the VASO + cohort.

Treatment:

Drug: Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan

No vasoactive-inotropic drug (VASO -)

Description:

Patients treated with vasoactive-inotropic drugs (epinephrine, norepinephrine, dobutamine, dopamine, and levosimendan) in the first 12 hours after Intensive Care Unit Admission (ICU) or patients never treated with such drugs in ICU were retrospectively classified in the VASO - cohort.